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Abstract 
 
This paper examines the direct-to-consumer genetic testing industry against the 
background of the current regulatory framework in New Zealand. Direct-to-consumer 
genetic testing refers to genetic testing services sold directly to consumers mainly via the 
Internet without the involvement of health care professionals. This paper focuses on 
disease predisposition genetic tests that calculate a personal risk to develop a disease 
based on genetic information. 
After an analysis of the peculiarities of DTC genetic testing services, the paper contrasts 
the main arguments for no further state intervention with the concerns about DTC genetic 
testing that call for more governmental oversight. The main part of the paper argues that 
the current partial coverage of the existing regulatory framework in New Zealand is 
insufficient. The paper presents possible recommendations for legislative reform, taking 
into account recently released details regarding a new Therapeutic products Bill.  
 
Word length 
The text of this paper (excluding abstract, table of contents, footnotes and bibliography) 
comprises exactly 11999 words.  
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I Introduction 
 
“Do you have a history of a genetic disease in the family or perhaps want to take 
better control of your health? Why not be more pro-active and manage your own 
health to the max by doing a genetic health test? Our genetic health test will 
determine your predisposition to 34 different diseases.”1 
 
The above slogan from the genetic testing company EasyDNA sounds promising.  Words 
such as  “better control”, “pro-active” and “max” management imply that the test offered 
is a feature of today´s cutting edge field of personalised health care. 
 
There is no question that the knowledge that researchers have gained about human 
genetic information in the past decades is remarkable. The completion of the Human 
Genome Project, which presented a mapping of the entire human DNA in 2003, was a 
cornerstone for further research exploring the influence of genetic material on the 
development of common diseases such as cancer, as well as on effectiveness or 
tolerability of specific medicine. 
 
The research is still in its initial stages. Nevertheless, private companies have discovered 
a new market: direct-to-consumer (DTC) genetic testing services. This term refers to 
genetic testing services sold directly to consumers via the Internet or other marketing 
venues without the involvement of healthcare professionals.2 According to industry 
analysts, the worldwide market of DTC genetic testing will have a value of USD 230 
million by 2018.3 While the offered purpose of genetic analysis is manifold, from well-
known paternity testing, to ancestry tests right through to animal tests;4 this paper will 
focus solely on health-related tests. Of particular interest are predictive tests that are 
marketed as a means to obtain a personalised risk assessment for the development of a 
certain disease.5  
  
1  See slogan on www.easydna.co.nz (accessed on 22nd of March 2016). 
2  Pascal Su “Direct-to-Consumer Genetic Testing: A comprehensive View” (2013) 86 Yale Journal of 
Biology and Medicine 359 at 359. 
3  “Future of Direct-to-Consumer (DTC) Genetic Testing Market Remains Fraught with Challenges, 
According to New Report by Global Industry Analysts, Inc.” (8 August 2012) <www.prweb.com>. 
4  Easydna offers genetic tests for animals, however this kind of test is currently not available on the New 
Zealand website.  
5  Other forms of health related tests are pharmacogenetic tests, which measure individual variability in 
drug metabolism and nutrigenomic tests that make claims for personalized diet and nutrition for optimal 
weight loss. 
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This paper aims to evaluate DTC genetic testing for consumers from a  New Zealand  
perspective. The first part of the paper gives an introduction to the DTC service and 
explains the current scientific background of the tests. The chapter ultimately identifies 
the main peculiarities of DTC genetic testing. The following part contrasts the idea of a 
free market access for DCT genetic tests with current concerns that call for particular 
regulation of this new industry. It concludes that the main factors that make an 
unregulated market problematic are the high risk of consumers being misled about the 
validity and the usefulness of the test results, the issue of informed consent in a business-
consumer relationship and possible negative impacts on individuals and society. The 
main part of the paper argues that there is a lack of the current regulatory landscape to 
sufficiently address theses issues and makes recommendations as to how an appropriate 
level of regulatory oversight can be reached.6 The recommended approach is one that 
focuses on quality requirements, pre-market approval and partial involvement of health 
care professionals. The current revision of the Medicines Act 1981 is an opportunity to 
reform the law so that it comprehensively deals with the issues of genetic testing. 
 
II The Service of Genetic Testing Companies  
To answer the question whether and to what extent the business model of DTC genetic 
testing needs regulatory intervention, it is important to know the basic function of the 
service, as well as the science behind the service. 
A How Does the Service of Genetic Testing Companies Work? 
Two DTC genetic testing companies, which operate on the New Zealand market, serve to 
illustrate the service.7 Both companies, EasyDNA and International Biosciences (IB) 
operate their business internationally with a branch office in New Zealand.8 The so-called 
DNA Health Test (EasyDNA) or Genetic Predisposition Test (IB) is offered for 695 NZD 
and claims to “reveal invaluable information about your lifetime risk towards 34 major 
diseases”.9 The list of diseases includes inter alia Multiple Sclerosis, heart diseases, 
  
6  The paper acknowledges the potential privacy issues related to DTC genetic testing services but the issue 
is not covered by the paper due to word count restraints. 
7  See www.ibdna.co.nz and www.easydna.co.nz. 
8  According to their New Zealand website both companies provide a company address in Auckland: 
International Biosciences Inc “Contact us” <www.ibdna.co.nz>; EasyDNA “Contact us” 
<www.easydna.co.nz>. 
9  EasyDNA “Why take our DNA health test?” <www.easydna.co.nz>. 
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Alzheimer´s disease, obesity, migraine, diabetes and different kinds of cancer, including 
breast cancer.  
 
After ordering online, consumers get a genetic sample collection kit sent to their home 
address. Consumers do a simple cheek swab with the provided cotton swab and send the 
sample, along with a signed consent form, back to the company’s address in New 
Zealand.10 Genetic counselling by a health care professional prior to the test is not 
mandatory, however, both companies provide a call back service if assistance is needed. 
EasyDNA additionally provides the possibility of a Live Chat with a DNA Consultant. 
Yet, information about the qualification of the employed consultants is not available on 
EasyDNA’s website. 
 
After analysis of the sample by the testing companies’ partner laboratories, consumers 
receive their results online. EasyDNA does only provide a small image cut-out of the 
complete test result report on their website. Surprisingly, the report-excerpt provided by 
EasyDNA is identically to the sample result report available on IB´s website. Although 
evidence to validate this hypothesis could not be found, a collaboration of both 
companies regarding the interpretation of the test results is possible. The first page is an 
introductory page with general information. On the next page consumers see a summary 
table showing each disease with the corresponding average risk in population next to the 
calculated personal risk of disease. The following image shows one example of the 
detailed description for each disease that is provided after the summary: 
 
 
 
 
 
 
 
Image 1: Extract of an sample test result report (Source: GeneWell DNA test 
report, available on International 
Biosciences<https://www.ibdna.co.nz//app/uploads/2015/10/GeneWell_demore
port_28092015.pdf>, last accessed 29th March 2016). 
 
  
10  EasyDNA “DNA Sample Collection Instructions” <www.easydna.co.nz>; International Biosciences 
“Genetic Predisposition Test Sample Collection” <www.ibdna.co.nz>. 
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At the end of the report, there is a section headed ‘Scientific Information’ with the raw 
data of the test. This section includes the different genetic markers, which the sample was 
tested for, and shows corresponding absence or presence in the sample. The information 
consists of a sequence of numbers and letters. The scientific information alone is of 
questionable value for lay consumers, as they will need further assistance to understand 
the meaning of the number combinations.  
B The Genetic Science Behind the Service  
The scientific information section with the raw analysis of the sample provides the 
starting point of DTC genetic testing. Contrary to what a person encountering the idea of 
DTC genetic testing for the first time may think, companies do not yet sequence the 
whole human genome. Despite constantly declining costs for an entire sequencing 
process, the majority of companies still do not consider whole genome sequencing as an 
economically viable mass product.11 Instead, the two companies taken as example in this 
paper, search for single nucleotide polymorphisms (SNPs). To understand the existence 
of SNPs in human body cells, it is useful to provide a short introduction into human 
genetics.  
 
The human genome is the information embodied in the 23 pairs of chromosomes found in 
the nuclei of most cells in the human body. Each chromosome consists of two 
intertwining strings of deoxyribonucleic acid (DNA). Each DNA string consists of a 
serious of nucleotides (up to 250 millions of nucleotides in one DNA string). There are 
four different types of nucleotides, which differ only in respect to their bases (adenine, 
thymine, cytosine or guanine).12 For simplification we name them A-,T-,C- or G-
nucleotide. What we refer to as genes is a specific region within the DNA strand or 
sequence of nucleotides. Those DNA regions lead alone, in cooperation with other parts 
of DNA and/or in interaction with environmental factors to certain biological traits. 
 
SNPs are alternations in the explained sequences of nucleotides in DNA strings. For 
example, a sequence that consisted of an A-nucleotide followed by a C- followed by a T-
nucleotide (ACT) is changed by replacing the A-nucleotide with a G-nucleotide (ACG). 
Such variations can occur during the copying process of body cells if the base of 
  
11  The first company to advertise sequencing of the entire human genome as a DTC-Service is advertised 
Sure Genomics. The US-based company offers its service for 2,500 USD and is currently taking pre-orders. 
The website does not contain any information whether the service will be available for non-US-citizens. 
<www.suregenomics.com>. 
12  Stephanie Bair “Direct-to-Consumer Genetic Testing: Learning from the Past and Looking toward the 
Future” (2012) 67 Food & Drug LJ 413 at 414. 
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nucleotides is miscoded. They are common in population and do not necessarily have a 
deleterious effect. In fact there are around 10 million SPNs in the whole genome and 
around 1 mutation in every 300 nucleotides.13 
 
In practice, companies use chips to track particular known SNPs in the DNA sample. The 
interesting question is: How do companies associate specific gene mutations with certain 
diseases and how do they assess a personal risk of disease accordingly? Not surprisingly 
companies rely on the current state of scientific knowledge.  
 
Genetic science can give definite results concerning monogenic diseases. Monogenic 
diseases are diseases that are caused by one particular gene mutation (or nucleotide 
sequence mutation) and lead to a one hundred per cent chance of developing the 
condition. Presence of the gene mutation is equivalent to a diagnosis to develop the 
disease in later life. Fortunately those single gene mutations that result in severe diseases 
are rather rare in population.14 Examples for monogenetic diseases are Huntington’s 
disease or Cystic Fibrosis.15  
 
In contrast, research is still in its initial phase regarding common multifactorial diseases. 
These diseases, which private genetic testing companies focus on, are caused by an 
complex interaction of different factors, where genetic mutations are – if at all – only one 
factor beside environmental causes and lifestyle.16 
 
Researchers hope to gain insight into the molecular aetiology of common diseases such as 
diabetes or cancer with so called genome-wide association (GWA) studies. GWA studies 
involve whole DNA sequencing of a large group of individuals with a particular disease 
and a control group without the disease in order to find common SNPs in the group of ill 
  
13  “What are single nucleotide polymorphisms (SNPs)?” (28 March 2016) Genetics Home Reference 
<www.ghr.nlm.nih.gov>. 
14  See World Health Organization “Monogenic diseases” Genomic Resource Centre <www.who.org>; 
Currently there are approximately 10,000 diseases known to be monogenic. The global prevalence of all 
monogenic diseases at birth is approximately 10/1000. 
15  National Human Genome Research Institute “Learning about Cystic Fibrosis” (last updated 27 
December 2013) and National Human Genome Research Institute “Learning about Huntington’s disease” 
(last updated 17 November 2011) <www.genome.gov>. 
16  National Human Genome Research Institute “What are genetic disorders” (last updated 10 November 
2015) <www.genome.gov>. 
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participants.17 Congruent SNPs among ill participants are said to be associated with the 
condition; however, they do indicate merely an increased risk to develop the disease, not 
a diagnosis. This means that the existence of the SNP does not imply that one will 
develop the disease, nor does its absence indicate that the person will not. Private 
companies use the SNPs that have been found in GWA studies to test genetic samples of 
their consumers exactly for those mutations and use algorithm programs to interpret the 
raw-data into a personal risk figure. 
C The Validity and Usefulness of the DTC Genetic Testing Results 
Unfortunately GWA studies at the current level of research have certain limitations that 
also have an impact on the validity and usefulness of DTC genetic testing results. The 
first important limitation of GWA studies is the risk of false positive associations.18 In 
fact, research shows that results of GWA studies are often disproved over time. As one 
example, among 32 SNPs associated with breast cancer none may actually be relevant for 
an increased risk to develop the condition, since, over time, subsequent GWA studies did 
not succeed in confirming the results.19 One possible reason for this development is the 
fact that early studies often focus on testing persons that have a strong familiar 
background of the particular disease, however, once general patients populations are 
assessed the SNP has a far smaller influence than initially assumed.20  
 
As a second limitation, GWA studies often show weak results in a sense that the relative 
increase of risk associated with the SNP is small compared to the non-carrier 
population.21 An analysis of 260 SNPs, which are associated with one or more common 
  
17  National Human Genome Research Institute “Genome Wide Association Studies” Frequently Asked 
Questions About Genetic disorders (last updated 27 August 2015) <www.genome.gov>. 
18  Michelle D Irick “Age of an Information Revolution: The Direct-to-Consumer Genetic Testing Industry 
and the Need for a Holistic Regulatory Approach” (2012) 49 San Diego L Rev 279 at 303. 
19  Helen Wallace “Direct-to-Consumer Testing” in Ulf Kristofferson, Jörg Schmidtke and JJ Cassiman 
(eds.) Quality Issues in Clinical Genetic Services (Springer Science & Business Media, 2010) 191 at 195. 
20  Giving this example for genetic predisposition for cancer: Peter Paul Yu, Julie M Vose and Daniel F 
Hayes “Genetic Cancer Susceptibility Testing: Increased Technology, increased Complexity” (2015) 
Journal of Clinical Oncology 1 at 2. 
21  There are a few exceptions like the breast cancer associated gene BRCA, however even as regards 
BRCA, doctors at the moment require as a second risk factor a strong familiar history of breast cancer: See 
Julian Barwell and Anirudh Kumar “Genomic Testing and Genomic Care: Are They Talking to Each 
Other?” (2015) 6(6) J Clin Res Bioeth 1 at 2. 
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diseases, found that the odd ratio is often only between 1.04 and 1.5.22 The odd ratio is a 
numerical expression, used in clinical research studies, to describe the odds of a condition 
given a particular exposure compared to the odds of the condition in the absence of that 
exposure. Hence, an odd ratio of 1.5 means that one has a fifty per cent increased risk if 
you carry a particular SNP. Fifty per cent does sound a lot, but the impression changes if 
one puts the result in relation to the often also low odds in the control group. If the risk in 
the control group is one per cent, the risk in the group with the SNP increases to 1.5 per 
cent.23 Another interesting detail is that even if all known SNPs for one specific disorder 
are taken together, they explain usually less than five to ten per cent of the prevalence of 
a disease, meaning that our knowledge about the influence of genes on disorders is still 
very limited.24 For example, 49 gene variations are known that contribute to an increased 
risk for the multifactorial disease type 2 diabetes, however, it is also true that the body 
mass index has a substantially higher influence on absolute risk than the genetic 
predisposition.25 
 
One explanation for the poor results of GWA studies could be that the whole picture of 
how genetic predisposition influences disease onset requires further discovery of relevant 
SNPs and – even more important – an intensive study on the interaction between multiple 
SNPs and/or interactions between SNPs and environmental factors.26 Another 
explanation could be that the influence of SNPs with a large prevalence in population on 
common diseases is in fact low and that the important SNPs that significantly impact on 
risk are rare in population. Unfortunately, GWA studies are not designed to detect SNPs 
which have little frequency in population.27 
 
All in all, based on the current low level of knowledge about the interplay of genetics, 
environment and lifestyle in regard to common diseases, the accuracy with which a test is 
able to predict a clinical condition is low. The so-called low clinical validity of most 
  
22  Michael Krawczak “Clinical Validity and Utility of Genetic Testing in Common Multifactorial 
Diseases” Ulf Kristofferson, Jörg Schmidtke and JJ Cassiman (eds.) Quality Issues in Clinical Genetic 
Services (Springer Science & Business Media, 2010) 157 at 162. 
23  Matthew Piehl “Regulating Hype and Hope: A Business Ethics Model Approach to Potential Oversight 
of Direct-to-Consumer Genetic Testing” (2011-2012) 16 Mich St U J Med & L 59 at 84, n 193. 
24  José A Riancho “Genome-Wide Association Studies (GWAS) in Complex Diseases: Advantages and 
Limitations” (2012) 8 (2) Reumatol Clin 56 at 57 <www.reumatologiaclinica.org>. 
25  Wylie Burke and Susan Brown Trinidad “The Deceptive Appeal of Direct-to-Consumer Genetics” 
(2016) Ann Intern Med (forthcoming). 
26  Wallace, above n 19, at 195. 
27  Krawczak, above n 22, at 162. 
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predictive genetic tests also explains why genetic testing for common diseases has not yet 
become a regular procedure in public healthcare systems.  
D Four Key Characteristics 
From the previous sections it is possible to identify a few characteristics of DTC genetic 
testing. Taken together, those characteristics create a service where consumers are 
particularly vulnerable and might need more protection than with normal consumer goods 
and services.  
 
Firstly, human DNA as the source that DTC genetic testing companies use, has some 
features that, in their combination, distinguish this kind of information source from other 
sources that are used to obtain predictive information in medicine.28 The human DNA is 
characterized by its eternity and unique nature. Genetic information cannot be altered; 
hence, any predictive medical information derived from the analysis of human DNA – 
provided its accuracy – has lifelong influence and is irreversible. In addition, despite the 
uniqueness of the human DNA, genetic information allows conclusions to be drawn about 
possible inherited risk factors for relatives.29 Furthermore, genetic information bears the 
risk of stigmatisation of particular ethnic groups if deleterious mutations of DNA can be 
associated with ethnicities. 
 
For any of the above-mentioned features, existing ways of medical risk prediction may 
have similar or the same effects. To name but one example, family anamnesis can also 
reveal irreversible risk factors for an individual. However, DNA bundles the 
aforementioned characteristics together and has, at least in this regard, a special role in 
predictive medicine.30 Additionally genetic testing will predominantly target consumers 
who do not show any disease symptoms. By contrast, traditional predictive medicine is 
often closely related to existing symptoms. The fact that consumers get the information 
  
28  All of the following arguments are also recognized by United Nations Educational, Scientific and 
Cultural Organization (UNESCO) International Declaration of Human Genetic Data 32 C/Resolution 24 
(adopted on 16 October 2003), Art 4. 
29  One example is the heritability of the BRCA gene mutation, which leads to a 80% risk increase to 
develop breast cancer. The possibility that a BRCA is passed to children by a parent-carrier is 50%: Chiyan 
Lau and Graeme Suthers “BRCA testing for familial breast cancer” (2011) 34 (2) Austr Presc 49 at 49. 
30  See Reinhard Damm and Steffen König “Rechtliche Regulierung prädiktiver Gesundheitsinformation 
und genetischer Exzeptionalismus” (translation: Legal Regulation of predictive health information and 
genetic exceptionalism) (2008) 26 MedR 62-70 who give a good overview of the related controversial 
discussion whether the special status of genetic information calls for special legal regulation.  
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‘out of the blue’ may influence how they apprehend and absorb the results of DTC 
genetic testing.31 
 
Another key feature of DTC genetic testing is the still developing scientific background 
upon which the test results are based on. Even if private companies have the best 
intentions in regard to clinically valid results and even if they use only SNPs that have a 
valid scientific substance, the black whole is enormous, because the SNPs currently 
known explain only a small fraction of the causation of diseases.32 For example, a 
calculated decreased risk due to the absence of a SNP may be wrong if the person carries 
other gene mutations whose relevance is not yet known. The insecurity in the scientific 
background is also reflected in ambiguous result reports. The Government Accountability 
Office (GAO), a US government agency, investigated the DTC genetic testing market in 
the United States under cover in 2010. The agency sent identical DNA samples to 
different companies in the United States.33 In their report they claim that results were 
“misleading and of no or no practical use to consumers” as “different companies often 
provide different results for identical DNA”.34 This finding is not surprising. The report 
itself concludes that contradictory results may be a result of a wide range of different 
possible SNPs that are used in testing or may occur due to self-made algorithms, which 
lead to different risk calculations if multiple SNPs for one disease are combined. Genetic 
experts in the GAO report confirmed that “each company’s results may be internally 
consistent, but not tell the full story” and that tests are “promising for research but the 
application is premature”.35 Following the report, the Federal Drug Agency has turned its 
attention to the DTC genetic testing industry since 2010 (see below IV).36  
 
Thirdly, the service of DTC genetic testing companies is characterised by a complete 
shift from a clinical setting to a commercial setting. Whereas traditionally the access to 
genetic testing was lead through a consultation with a doctor who ordered the test from a 
  
31  Damm and König, above n 30, 65. 
32  Wallace, above n 19, at 195. 
33  United States Government Accountability Office Direct-to-Consumer Genetic Tests: Misleading Test 
Results are Further Complicated by Deceptive Marketing and Other Questionable Practices (22 July 
2010). 
34  At 4–5. 
35  At 8. 
36  An overview of the developments in the USA gives Chelsea Weiermiller “The Future of Direct-to-
Consumer Genetic Testing: Regulation and Innovation” (2014) 16 NCJL & Tech On 137; and Flavia 
Horvath Chen “23andMe and the FDA: Negotiating Conceptions of Benefit in the Direct-to-Consumer 
Genetic Testing Regulatory Debate” (Thesis, University of Washington, 2014).  
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known laboratory, the DTC genetic testing market is based on a pure business-costumer 
relationship.  
 
Lastly the service is highly accessible, mostly anonymous and the entire process, from 
ordering until receiving the results, is handled by long distance communication. In 
contrast to a medical environment, the relationship between a company and a consumer 
lacks a long-term character. In most cases the interaction will be a one-off transaction.37 
 
III A Call for a Specific Regulation of the DTC Genetic Testing Market? 
Against the backdrop of the previous section, this section explores the arguments for and 
against further legal intervention to regulate the DTC genetic testing industry. It will first 
assess the arguments of the proponents of a DTC genetic testing market with as little 
intervention as possible. It concludes that the arguments of a highly accessible market are 
in parts acknowledged and should be considered during the development of any 
regulatory approach, however, the concerns that are consequences of the explored key 
characteristics call for a legal solution that goes beyond consumer protection for ordinary 
goods and services. 
A Arguments for an Unrestricted Market: Consumer Autonomy and Promotion of 
Research 
The central argument for little state intervention in the market that DTC genetic testing 
companies point out is individual autonomy and empowerment.38 From a health related 
point of view, free access to genetic information allows individuals to engage actively 
with their healthcare management and to take action where appropriate.39 Knowing one’s 
genetic risk factors, one can consider preventive measures as regular screenings or even 
prophylactic surgeries such as a mastectomy.40 Even if the genetic mutations are of little 
overall influence or their influence is not yet fully explored, individuals can try to 
minimise potential hazardous environmental factors and change their lifestyle 
accordingly.41 From a public health perspective such preventive measures may save 
resources and strengthen the sustainability of the healthcare system in the long term. 
  
37  Piehl, above n 23, at 86. 
38  See as one example the advertising slogans of one of the worlds largest DTC genetic testing companies 
23andme: “More than knowledge. Knowing what you can do.” <www.23andme.com>. 
39  Bair, above n 12, at 424. 
40  An extreme example in case of the breast cancer BRCA gene variation. 
41  Jennifer A Gniady “Regulating Direct-to-Consumer Genetic Testing: Protecting the Consumer Without 
Quashing a Medical Revolution” (2007-2008) 76 Fordham L Rev 2429 at 2436. 
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Interestingly, in a study in the United States of America, which accompanied test takers 
for a three-month and one year period, participants did not show any actual behaviour 
change after having received test results.42 Long-term studies are needed to show whether 
there is a beneficial impact on consumers’ health. 
 
Irrespective of an existing health benefit, either because the majority of test takers do not 
seem to adopt lifestyle changes or because there is simply no medical intervention 
available, one author argues for a wider notion of autonomy.43 Loi defines autonomy in a 
moral way. Individuals are the owners of their bodies and hence also the moral owners of 
their genetic materials as part of their bodies. As a consequence, it is a natural right of all 
individuals to do with their genetic material whatever they want, including paying for a 
genetic test, as long as they do not harm others.44 That right exists prior and independent 
from the quality of the information they receive from the test. According to this 
argument, it is indeed irrelevant whether the test results are useful for personal medical 
intervention. State authorities should not interfere with that right to ownership, unless 
there are considerations that justify restrictions such as negative effects to public health or 
another persons’ rights. 
 
It is a valid point that one should be able to explore genetic information that is inherently 
“personal” and that consumers have a right of ownership over their genetic material, 
which includes access to testing. However, even if one acknowledges such a right, state 
regulation may be necessary to enable consumers to make a decision about whether to 
use their genetic material in the first place. Governmental oversight would not pursue a 
restriction of access, but rather the creation of fair market conditions that ensure that 
consumers understand the chances and limits (especially regarding the clinical validity) 
of the test. Additionally accepting the argument that access should not be restricted due to 
lack of clinical utility leaves open the possibility to for other reasons. Interestingly even 
the proponents of a prima facie right to test do not deny that governmental intervention 
may be necessary to balance consumer’s market position.45 
 
  
42  Loredana Covolo and others “Internet-Based Direct-to-Consumer Genetic Testing: A Systematic 
Review” (2015) 17 (12) J Med Internet Res 1 at 5, n 92 and n 93. 
43 Michele Loi “Direct to consumer genetic testing and the libertarian right to test” (2016) J Med Ethics 
(forthcoming, published online first 23 March 2016) 1. 
44  At 1.  
45  At 3.  
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Consumer´s empowerment is also the basis of the second argument for a free DTC 
genetic testing market: The (perceived) benefit of having absolute control over their own 
data. DTC testing services, as they currently operate, offer the apparent advantage that 
consumers can decide whether or not to share the results with third persons, including 
their doctor. By contrast, the results of a genetic testing that are ordered by a physician 
become part of patients’ official medical records. Common concerns are that life 
insurance companies or employers can get legal or illegal access to this data and use it to 
a patient’s detriment. The results of a survey conducted amongst 1046 consumers of DTC 
genetic testing in the United States reflect a (perceived) feeling of a high standard of 
privacy protection in the DTC genetic testing industry. 36 per cent of the participants 
believed that their data was better protected in the private sector than it would be in the 
public sector.46  
 
This sense of control over the own data could be misconceived. There are new perils for 
data privacy that result just from the private, profit-driven market. Without going into 
detail, companies do currently not offer any information about what happens with data 
when a company goes bankrupt or mergers with another company.47 Considering that the 
generated risk reports are an extremely valuable company asset, it is not unlikely that 
personal data may fall into hands of third parties without consumer’s consent. 
 
A further argument for little state intervention in the DTC genetic testing industry is the 
use of collected data as primary research tool.48 The US based company 23andme, which 
currently excludes New Zealand consumers from their testing service, offers the 
possibility for customers to contribute their test results to a research database.49 23andme 
has recently partnered with two big pharmaceutical companies, inter alia for research on 
Parkinson’s disease.50 However, 23andme’s motives seem far from altruistic. In an 
interview in 2013, Patrick Chung, a member of the company’s board, said “once you 
have the data, [the company] does actually become the Google of personalised health 
  
46  Juli Murphy Bollinger, Robert C Green and David Kaufman “Attitudes About Regulation Among 
Direct-to-Consumer Genetic Testing Customers” (2013) 17 Genetic Testing and Molecular Biomarkers 424 
at 426. 
47 See as an example for many: European Academies Science Advisory Council and Federation of 
European Academics of Medicine Direct-to-consumer genetic testing for health related purposes in the 
European Union (July 2012) at 4.3. 
48 At 2.6; with further references. The report acknowledges the chance of enhanced research but also sees 
the necessity to establish appropriate rules for obtaining informed consent. 
49  23andMe “Accelerating research. A new way” (2016) <www.23andme.com>. 
50 23andMe “Accelerating research. A new way” (2016) <www.23andme.com>. 
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care”.51 One can conclude from this statement that genetic testing companies consider the 
data as an extremely profitable company asset, probably economically more attractive 
than their primary field of business, the selling of testing kits. Having this financial 
interest in mind, it is especially important that current concerns (see following section B 
2) about obtaining proper consumer’s consent are addressed.  
B Concerns that Call For Specific Legal Intervention  
The arguments that proponents claim in favour of a free DTC genetic testing market are 
offset by an extensive list of concerns, which are shared by people working in the health 
care sector as well as scientists and scholars in the field of ethical and medical law. 
1 Consumers are misled about the validity and usefulness of the product 
One peril of DTC genetic testing is that the interpretation and communication of test 
results bear a high risk that consumers are mislead about the validity of the test as well as 
the usefulness of the test.52 
 
(a) Misled about validity of the test 
Regarding the validity of the test, the results might suggest a clinical validity that 
currently cannot be achieved.53 Clinical validity, as described in the first part of this paper 
(see above B), refers to how well a genetic variant is related to the risk of a certain 
disease. Due to the complexity of genetic science and a general asymmetry of knowledge 
between consumers and the company, it is barely possible for consumers to assess the 
reliability and accuracy of the test and it is likely that consumers consider the results to 
have a greater significance than they actually do. A close look on the websites of 
EasyDNA and IB reveals that information is often incomplete and the design of the test 
results are likely to result in consumers misunderstanding the validity of results. 
 
Prior to the purchase of the test, EasyDNA’s website does not contain any information 
about the SNPs that are included in the test or how the company calculates the overall 
risk if – as in most cases – more than one mutation is relevant for the disease. By 
  
51 Quote from Patrick Chung, a companies board member cited in Charles Seife “23andMe is Terrifying, 
but not for the Reasons the FDA Thinks” (27 November 2013) Scientific American 
<www.scinetificamerican.com>.  
52 This point is made often in the literature, see:  Nuffield Council on Bioethics Medical profiling and 
online medicine: the ethics of ‘personalized healthcare’ in a consumer age (Nuffield Press, Oxfordshire, 
2010) 142 at 158; Irick, above n 18, at 305; but Kathryn Schleckser “Physician Participation in Direct-to-
Consumer Genetic Testing: Pragmatism or Paternalism” (2012-2013) 26 Harv J L & Tech 695. 
53 Irick, above n 18, at 305. 
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contrast, IB informs consumers on their website, in a prominently placed paragraph, 
about the nature and the limits of genetic testing and includes that “rare variations that 
affect certain diseases may not be covered by a SNP test as they still have not been 
discovered, or because their incidence is very low”.54 According to IB, results are based 
on “latest scientific research” and the used studies “yield[s] a lot of confidence”, 
however, IB admits that this does not “exclude the possibility that future research may 
improve upon the accuracy of the results”.55 Although better than EasyDNA, it is worth 
noting that the company only mentions the improvement of accuracy through further 
research, not the possibility that the association of an SNP with a disease could be 
disproved and thus results may lose any significance at all. 
 
Additionally it is doubtful whether a simple disclaimer is sufficient for consumers to 
understand the uncertainty inherent in current genetic knowledge. Even if information is 
provided on the website, as one writer points out “businesses exploit the persuasive 
power that scientific information tends to have on lay individuals”.56 That argument 
refers to the risk analysis report. As explained in the first chapter, companies do not only 
report the existence of SNPs, they also interpret results in a graphic way together with 
explicit percentage information. The use of a definite number itself has the potential to 
represent an accuracy and validity that allows prior warnings about the inherent 
insecurities recede into the background. Consumers are used to numbers in science and 
usually they are the result of precise calculation. What remains in consumers’ mind is 
more likely to be the number or graphic, not a disclaimer at the end of the page.57 
 
(b) Misled about usefulness of test results 
As a consequence of the perceived validity of the test, consumers may also be misled 
about the usefulness of a test. To answer the question of when consumers are likely to be 
deceived about the utility of the test, it first has to be considered what consumers consider 
to be a useful test and whether their expectations are met by the test results. 
  
54 International Bioscience Inc “Genetic Predisposition Test” (accessed 11 April 2016) 
<www.ibdna.co.nz>. 
55 International Bioscience Inc “Genetic Predisposition Test” (accessed 11 April 2016) 
<www.ibdna.co.nz>. 
56 Irick, above n 18, at 284. 
57 Along these lines is also the argument of Sophie Yohe quoted in Bryon Nelson “The Big Sell: Direct to 
consumer tests promise patients more abundant and accessible information, but potential pitfalls abound” 
(2016) 126(1) Cancer Cytophatology 7 at 8, who said “Numbers can be kind of deceiving if you don’t 
really know what they mean or have the proper context, and I think that’s one of the problems with a lot of 
direct-to-consumer tests.” 
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A direct answer to this question is difficult considering that the usefulness of a test is 
something subjective that depends on the purpose of the test and the value of results in 
relation to the purpose. Traditionally a test is considered useful if it shows clinical utility. 
This term refers to the ability of the test to lead to improved health outcomes for the 
patient.58 An improved health outcome can consist of medical intervention by preventive 
or therapeutic options. However, even if no clinical intervention is possible, e.g. with the 
Huntington’s disease, genetic testing is considered clinically useful if it has beneficial 
psychological and practical benefits for the test taker that outweigh potential harms. 
Certainly, the assessment whether the results are useful from a health care perspective 
takes into consideration the clinical validity of the test and a cost-benefit analysis, too. As 
an example, genetic testing for Alzheimer´s disease is not considered as valid enough to 
present reliable information. Consequently it cannot provide clinical useful information 
and public resources should not be spent on such testing. 
 
In DTC genetic testing, however, utility should be defined in a broader sense as personal 
utility.59 To argue that results have no subjective value because they cannot be considered 
clinically useful (yet), ignores that consumers do not rely on public resources and are in 
general allowed to spend their money on anything they want. Just because a physician 
does not consider the result useful, does not mean that a consumer cannot consider it 
useful. However, consumers are misled if they consider the genetic test to have a 
perceived utility that the test actually does not have. The following example will show 
that the threshold to be misled can be low due to the complexity of genetic testing: 
Assume that a woman undertakes a genetic testing for the BRCA1 or BRCA2 gene that, 
according to current research, increases the risk to develop breast cancer. Assume that the 
test comes back negative. It is likely that the women feels relieved that she is not at a 
higher risk for breast cancer. The perceived utility of the test is to feel reassured about 
breast cancer. However, the test is in fact only useful to the extent that it shows that this 
specific mutation does not exist and does not say anything about another, perhaps still 
unknown, mutation that may put the woman at the same risk.60  
 
A wrong perception about the usefulness of the test can also be obtained after the 
purchase of the testing kit following a misinterpretation of the test’s significance. One 
must differentiate between the motive to take the test in the first place and the perceived 
  
58 Eline M Bunnik, A Cecile JW Janssens and Maartje HN Schermer “Personal utility in genomic testing: 
Is there such a thing?” (2015) 41 J Med Ethics 322 at 322. 
59  See for this new term in regard to DTC genetic testing Bunnik, Janssens and Schermer, above n 58. 
60  Example taken from Bunnik, Janssens and Schermer, above n 58, at 325. 
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value a person put on results after taking the test. In fact various studies show that one of 
the main reasons why consumers participate in DTC genetic is the mere curiosity about 
their genetic make up.61 However, once they get the interpretation of their genetic raw 
data, there is a danger that they will draw their own conclusions and relate the results to 
their health status. It is the task of legislators to evaluate how much further information or 
assistance consumers need to assess the informative value correctly.  
2 Concerns about informed consent   
One of the most important concerns about DTC genetic testing is whether companies 
outside a medical setting can guarantee effective informed consent of consumers 
regarding the analysis of their DNA and the disclosure of results.62 Firstly, this part of the 
paper explores why the ethical duty of informed consent, traditionally developed in a 
health care environment, should also apply to the business-consumer relationship of DTC 
genetic testing. After that it points out why current DTC genetic testing providers in a 
highly unregulated market are unlikely to meet the requirements of informed consent. 
Apart from general deficiencies of information disclosure, the particular case of testing of 
minors and companies’ additional use of genetic data for research purposes is discussed. 
 
(a) Does the concept of informed consent apply to DTC genetic testing? 
Informed consent is the realisation of autonomy in a health care environment. It is 
ethically required for any medical intervention and consists of the patient’s autonomous 
decision to pursue a particular treatment. As the term informed consent implies, it is the 
result of a process. This process includes the disclosure of all relevant information, 
including benefits and risks of the treatment, and their understanding by the patient to 
enable him to make an autonomous decision.63 Hence, the concept of informed concept is 
different from an autonomous decision in a day-to-day purchase, because it is the ethical 
duty of the doctor to disclose necessary information and to establish understanding in a 
situation where a knowledge asymmetry exists. Doctors act on a fiduciary basis and are 
obligated to neutrally inform the patient in their best interest.64  
  
61  Mauro Turrini and Barbara Prainsack „Beyond clinical utility: The multiple values of DTC genetics“ 
(2016) 8 Applied & Translational Genomics 4 at 5. 
62  This argument can be found often in literature, see: Bair, above n 12, at 417; and Elinne M Bunnik, A 
Cecile and Maartje Schwermer “Informed Consent in Direct-to-Consumer Personal Genome Testing: The 
Outline of a Model Between Specific And Generic Consent” (2014) 28 Bioethics 343–351. 
63  Bunnik, Cecile and Schwermer, above n 62, at 344–345. 
64  See for example New Zealand Medical Association Code of Ethics for the New Zealand Medical 
Profession (May 2014), which lays down principles of ethical behaviour, applicable to all doctors including 
20 Direct-to-Consumer Genetic Testing in New Zealand 
 
 
At first glance, one could ask whether any DTC genetic testing should be subject to the 
special requirements of medical informed consent at all. After all, the DTC genetic 
services companies act outside the traditional medical environment and emphasise that 
their services do not provide any health care but only present information for educational 
or informational purpose.65 Perhaps DTC genetic testing is no different from any other 
sales contract. Similar to financial service contracts, risks can be disclosed in an 
appropriate form on the website. Commercial providers have – in contrast to doctors – 
not taken an oath to act in the interest of consumers and consumers know this. If DTC 
genetic testing services are seen like this then there should be no obligation on the service 
providers to put consumers’ interests before their own business interests. Normal 
constraints applying to false or misleading claims for DTC genetic testing should be 
considered sufficient.66  
 
The idea that DTC genetic testing services are outside the medical arena and like any 
other consumer service is unconvincing. The health-related purpose of genetic testing 
cannot be denied. The companies themselves make numerous health-related claims on 
their websites.67 The results may be informative, but companies interpret the information 
with regard to health care. The mere fact that they operate on a commercial model is not 
sufficient to exclude enhanced ethical requirements. Due to the peculiarities of genetic 
data and the possible negative psychological and social effects, genetic testing services 
are in their nature different from other risk-related consumer contracts. In the same way 
that companies profit from blurring the boundaries between commerce and medicine, 
they should also have to accept that they are obligated to comply with medical ethical 
standards.68 
 
(b) Possible issues in relation to informed consent? 
The first issue is the form of disclosure of information. Due to the lack of mandatory pre-
counselling by a trained professional, consumers are left with only the written 
information on the website. Written information is not always less effective than 
                                                                                                                                                 
those who may not be engaged directly in clinical practice. It also includes recommendations for ethical 
practice. 
65 See International Bioscience “Scope of Genetic Testing” Genetic Predisposition Test 
<www.ibdna.co.nz>; See EasyDNA “Terms and Conditions: Genetic Predisposition Test” 
<www.easydna.co.nz>. 
66  Bunnik, Cecile and Schwermer, above n 62, at 346. 
67  See introductory quote, above n 1. 
68  Bunnik, Cecile and Schwermer, above n 62, at 348. 
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information provided in a face-to-face conversation. Written information can be 
scrutinised carefully and be read several times in order to fully comprehend the content. 
On the other hand, online disclosure means that it is up to the consumer to search for all 
available information and to combine information where it is necessary. Furthermore, in 
case of additional questions, it is a bigger obstacle for consumers to email or call the 
company than it would be in a face-to-face conversation. 
 
Additionally, because of the commercial character of DTC genetic testing, information is 
often presented in the form of Terms and Conditions (TAC). EasyDNA presents its TAC 
at the last step of the order in form of a box click mechanism. TAC can voluntarily be 
accessed by a click, but to process the order it is only necessary to a click a box. Ignoring 
the fact that most consumers are reluctant to study TAC in online purchase contracts, 
opponents rightly claim that “TAC are not associated with the moral obligation to ensure 
understanding in the way in which informed consent is”.69 TAC are used on a contract 
law basis to exclude liability, define duties and rights and as a written documentation in 
case of a dispute. They have certain informational value but they are not written to 
promote understanding of the service.  
 
The second issue refers to the content of information that is disclosed by DTC genetic 
testing companies. Here again, the blurring of boundaries between medicine and 
commerce is a challenge. Undoubtedly, information provided in a commercial 
environment is given to inform as well as to persuade. Even if companies disclose risks, 
this may appear in small font in the TAC or with a disclaimer, whereas benefits are 
presented prominently. In contrast to the fiduciary relationship in a clinical setting, the 
appearance of a conflict of interest between the aim of profit maximisation and a 
balanced information disclosure is more likely. In a medical setting a potential conflict 
between financial interest and ethical standards may also arise, however, it is more often 
tempered by intermediaries such as insurance payments, which guarantee that 
professional advice is not jeopardised by potential financial motivations.70 As a practical 
example of poor risk disclosure, the website of EasyDNA does not mention the risk of 
possible psychological consequences upon knowledge of test results, nor does it address 
the issue of consumer’s possible duty to disclose results to insurance companies or the 
issue of data theft once the results are processed online. Quite the contrary, Easy DNA 
explicitly excludes any liability for consequences of test taking in its TACs. EasyDNA 
  
69  Bunnik, Cecile and Schwermer, above n 62, at 348. 
70  Piehl, above n 23, at 85. 
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does not seem to be the exception. Studies, which analysed various providers in the US 
market, affirm poor risk information dissemination.71 
 
The last issue does not focus on the preconditions for informed consent but rather 
highlights the question whether DTC genetic testing can ensure informed consent at all. 
Because of the anonymous environment of the transaction, providers can never totally 
ensure that the source of the sample and the consumer of the service are identical. This 
opens the possibility that samples are analysed without any consent at all.  
 
In the case of testing of minors, proper consent seems especially challenging. The process 
of informed consent also includes the option not to undertake a certain test. The right not 
to know is strictly personal, so that a child should be preserved the right to make an 
autonomous decision as an adult.72 However, in regard to genetic tests exceptions to this 
general rule of a “right to an open future” apply, when a genetic test is deemed to provide 
effective intervention possibilities that outweigh possible harm.73 In this case, consent by 
the legal representatives is sufficient. It is important to recognise that traditionally it is the 
medical professional who safeguards the child’s right not to know and may possibly 
decide against parents’ wish for testing.  
 
In the context of commercial DTC genetic testing such safeguards are absent. 
Furthermore, companies, such as EasyDNA, offer a “Children´s DNA Discovery Test” 
and encourage genetic testing of minors with advertising claims like “Thinking of testing 
your family or loved one at the same time? We offer discounts for tests involving more 
than one person”.74 In regard to predisposition testing, one can argue that genetic testing 
for children is overall beneficial with the philosophy “the sooner the better”. Despite the 
low clinical validity of current tests, results could still be used for adoption of a healthier 
lifestyle, which admittedly can only be beneficial to a child. Furthermore the test itself (a 
cheek swab) bears no risk at all. However, one may justifiably wonder whether there is a 
  
71  Covolo and others, above n 42, at 8, n 115,116,122,128. 
72  Pascal Borry and Heidi Carmen Howard “Is There a Right Time to Know?: The Right Not to Know and 
Genetic Testing in Children” (2014) 42 J L Med & Ethics 19 at 21. 
73  There are several guidelines for healthcare professionals that clarify when genetic testing of minors is 
ethically justified, see for Australasia: Human Genetics Society of Australasia “Guideline: Pre-symptomatic 
and Predictive Testing for Children and Young Adults” (August 2014) <www.hgsa.org.au>; for Europe: 
European Society of Human Genetics “Genetic testing in asymptomatic minors: recommendations of the 
European Society of Human Genetics” (2009) 17 European Journal of Human Genetics 720–721. 
74 EasyDNA “DNA Health Test” <www.easydna.co.nz>. 
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need for a genetic test to enable a healthy way of living and whether this argument is 
equally valid in regard to diseases with no possibility of intervention.  
 
The Children’s DNA Discovery Test does not focus on disease risk prediction but rather 
includes harmless sounding information about possible physical and behavioural traits. 
The company claims to indicate the height of the children, what kind of sports may suit 
them the most, their capacity of memory or whether they are a night owl or an early bird 
and lure parents with the idea of parental support tailored to a child’s strength and 
weaknesses.75 Irrespective of the doubtful clinical validity of the mentioned tests, such 
tests are more likely to serve the curiosity of parents than provide actual benefits for 
children. Moreover, potential harm for children is not only the loss of future adult 
autonomy, but also an impact on the child’s self-esteem and personal development, a 
distortion of the family’s perception of the child and the possibility of future 
discrimination.76 State regulations could help to safeguard the right of each individual to 
decide autonomously on the use of their own genetic data.  
 
Ultimately, the current practice of EasyDNA obtaining consent for use of the genetic data  
in research should be considered. According to the specific TAC for the Genetic 
Predisposition test, samples “may be disposed of or retained indefinitely for research (by 
your choice)”.77 Consumers are asked to indicate their choice in a form sent together with 
the testing kit. Yet, TAC also state that a “failure to indicate (my) preference will be 
taken as an acceptance to use (my) samples”.78 Such an assumption of consent is contrary 
to the idea of deliberate choice as the result of the informed consent process. Companies 
should be forbidden to include informed consent requirements in their TAC. 
3 Psychological harm 
A further issue is the psychological effect that the test results can have. It cannot be ruled 
out that knowledge about an increased risk of disease can be a heavy burden for the test 
taking person itself as well as for relatives. To know that one has an increased risk can be 
as distressing as to have a definitive diagnosis or even worse, because it does not present 
a definite answer. The psychological effect can be of particular importance in the case of 
severe diseases with no possibility for medical intervention. One example is the currently 
  
75 EasyDNA “Children’s DNA Discovery” <www.easydna.co.nz>. 
76 Borry and Howard, above n 72, at 24. 
77 It is worthy of mention that the Terms and Conditions provided via link at the last step of the purchase 
process vary from those Terms and Conditions provided on the bottom of the main page. The latter appears 
to relate more likely to genetic testing with other purposes, eg paternity testing.  
78 See EasyDNA “Terms and Conditions: Genetic predisposition test” <www.easydna.co.nz>.  
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offered testing for mutations of the APOE gene, which is said to increase the risk for 
Alzheimer’s.79 Knowing one’s personal risk factor could also have a social impact. Do I 
feel obligated to tell my partner that I am on a high risk to develop an incurable disease? 
Do I feel guilty because I know that my carrier status of the breast cancer gene BRCA is 
likely to have been passed on to my daughter?  
 
DTC genetic testing companies often rightly invoke the fact that most studies at the 
moment seem to rebut a negative psychological impact. In one US study fewer than 30 
per cent declared to feel anxious about a test result that showed increased risk.80 Other 
studies revealed that initial anxiety tends to reduce over time and is equal to non-test 
takers one year after test taking.81 However, current studies have an important limitation: 
They are usually based on a small sample size, low response rates and participants were 
prevailingly highly educated in the field of genomics (e.g. employees of health and 
technology companies).82 Therefore, findings may not be representative for the general 
public. Furthermore, studies at the moment are not able to display a long-term impact due 
to the rather new industry. 
4 Negative effects on society and burden for public health care 
A long-term negative impact on society is another concern of DTC genetic testing. As 
shown, consumers of DTC genetic testing are mostly healthy individuals who do not 
show any disease symptoms. If consumers overestimate the strength of the risk-
assessments, society could develop a “worried well” attitude. This term relates to a 
scenario where individuals rely more on their genetic predisposition than on their actual 
state of health. Even if they show no clinical signs of disease, they perceive their genetic 
predisposition as “inevitable destiny”. In that way society could also change its 
perception towards illness and label the mere existence of certain mutations as 
pathological.  
 
One may rightly counter that the scenario of a worried well culture is an overly 
pessimistic view without evidence. Nevertheless, two things should be stressed: Firstly, 
DTC genetic testing is a rather new phenomenon, which inevitably leads to the fact that 
no definite evidence based claims can be made about future social impact. Secondly, the 
  
79 See www.easydna.co.nz. 
80 Covolo and others, above n 42, at 5,n 90 and 94. This article provides an excellent review of recent 
research on different impacts of DTC genetic testing. 
81 At 5, n 88. 
82 At 12. 
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government arguably has the responsibility to prevent a situation where DTC genetic 
testing lays the foundation for such a social development, even if harm is not yet evident. 
That responsibility is toward today’s society, especially against the background of a 
possible future integration of genetic testing in public health care, but also toward future 
generations whose social values will depend on our approach to DTC genetic testing. 
 
Lastly DTC genetic testing could be a burden on health care if consumers take their 
results to their doctor. Consumers could ask for preventive screenings that have not been 
medically indicated. However, early research does not provide reliable results proving a 
negative impact of DTC genetic testing on public health care.83 Additionally, to get a 
balanced view, one must also consider possible cost savings for public health care, where 
the onset of disease can be prevented with medical intervention.84  
 
Another impact could be less concerning from an economic point of view, but reveals 
challenges regarding the approach medical professionals take towards DTC genetic 
testing. If medical professionals are confronted with DTC genetic testing results, they 
will most likely be reluctant to give medical advice upon results, because there is 
currently no way for doctors to verify the clinical validity of tests. At the moment health 
professionals in New Zealand are rarely confronted with DTC test results, however with 
decreased costs for testing and development towards whole genome sequencing, doctors 
will be in the front line to deal with this overlap between industry and medicine.85  
 
IV Possible Regulation 
Before going into detail, it can be said that the general aim of every governmental 
intervention with the DTC genetic testing market should be to provide a solution that 
minimises the above-mentioned concerns, but also acknowledges that any restriction of 
the personal right to access genetic information must be as minimal as possible.  
  
  
83 Covolo and others, above n 42, at 5–6. 
84 Bair, above n 12, at 423. 
85 Gemma R Brett and others “An exploration of genetic health professionals’ experience with direct-to-
consumer genetic testing in their clinical practice” (2012) 20 European Journal of Human Genetics 825 at 
826; In that survey conducted between 168 genetic health professionals in 2011 in Australia and New 
Zealand only 11 per cent of the participants reported one or more clients referred to them after undertaking 
DTC genetic testing. Likewise only 7 per cent felt confident in explaining and interpreting DTC genetic 
testing results. 
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Surprisingly perhaps, New Zealand has overlooked the issue of DTC genetic testing 
during the last decade. In fact, the last time the issue of genetic testing was on the 
political schedule was in 2003, when the National Advisory Committee on Health and 
Disability issued its report about Molecular Genetic Testing in New Zealand.86 Although 
the report only reviewed genetic testing in a clinical setting, the experts already 
highlighted certain risks, as for example the lack of quality assessment for genetic tests.87 
Certainly, this issue is even more urgent in a DTC environment. 
 
A comparative view shows that several jurisdictions have grappled with setting an 
appropriate level of regulation. Solutions are diverse and still developing. Representing 
an extreme protective approach, Germany has enacted the Human Genetic Diagnostics 
Act (Gendiagnostikgesetz). It provides for genetic testing exclusively in a medical setting 
and contains extensive provisions in regard to mandatory pre- and post counselling and 
the disclosure of the results through a medical professional.88 However, in several other 
European countries, the marketing and purchase of DTC genetic tests is still legal.89 Since 
2012 the European Union has been working on the creation of a harmonised approach. 
Current negotiations demonstrate how controversial the topic is. Whereas the 
amendments made by the European Parliament correspond to a large extent with the 
German position because the proposal requires medical prescription for any genetic 
testing and bans DTC advertising of genetic tests, the Council of the EU has a different 
view. The European body representing Member States governments did not accept the 
inclusion of those amendments in its proposal.90 The European Parliament’s proposal was 
also criticised by stakeholders as a disproportionate solution because it fails to take into 
  
86 See National Advisory Committee on Health and Disability “Molecular Genetic Testing in New 
Zealand” (October 2003). The National Advisory Committee is a part of the ministry of health and provide 
independent expert advice to the Minister of Health. 
87 At 6. 
88 Gendiagnostikgesetz (GenDG). 
89 Countries where currently no specific legislation that relates to DTC genetic testing exists are, for 
example, the United Kingdom and the Netherlands. See for an overview of current legislation in Europe 
Pascal Borry and others “Legislation on direct-to-consumer genetic testing in seven European countries” 
(2012) 20 Eur J Hum Genet 715–721.  
90 See for the proposed amendments by the European Parliament: European Parliament Legislative 
resolution of 2 April 2014 on the proposal for a regulation of the European Parliament and of the Council 
on in vitro diagnostic medical devices P7_TA(2014)0267 (2 April 2014)<www. europarl.europa.eu>. In 
contrast see for Council´s position: Council of the European Union Proposal for a Regulation of the 
European Parliament and of the Council on in vitro diagnostic medical devices (21 September 2015) 
(12042/15 PHARM 37 SAN 282MI 568 COMPET 411 CODEC 1194). 
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consideration that each type of test bears different risks and benefits for consumers.91 In 
the United States, the Federal Drug Agency was initially reluctant to intervene, because 
DTC genetic test services were classified as Laboratory Developed Tests, which are tests 
that are usually not subject to pre market approval. However, in 2013 the agency started 
to classify the tests as high-risk medical devices and requires pre-market approval, which 
includes the submission of clinical evidence.92 In Australia the supply of DTC genetic 
testing has been prohibited since 2014.93 There are voices in the literature, which favour 
an equally strict approach in New Zealand.94 Due to the possible future ethical, social and 
personal risks, one should “keep[ing] the genie in the bottle until such time as its magic 
powers can be adequately assessed”.95  
 
The following chapter will assess whether, and to what extent existing New Zealand law 
already applies to DTC genetic testing and how a balanced approach between an extreme 
protective state intervention and an overly liberal approach can be found. The discussion 
is structured upon the topics identified as the major concerns of DTC genetic testing.  
A Reducing the Risk of Misleading Information through Quality Assurance 
Irrespective of the type of goods, consumers expect to get what they have paid for. 
Hence, the aim must be to avoid consumers being misled about what they are buying and 
what it can be used for. That aim applies to information given in advertisements prior to 
the purchase decision as well as to the information provided by the test results. The 
industry of DTC genetic tests must comply with general consumer protection laws. 
However, considering the difficult scientific information, more positive regulation is 
needed. Especially in regard to the most essential part of the test, the test report, product 
quality standard is absent. The current provisions of the Medicines Act 1981 do not apply 
to the information provided in the risk-report. Therefore the focus of the 
recommendations lies on a certain level of clinical validity, meaning a valid link between 
the disorder and the genetic variant that should be guaranteed.  
 
  
91 Philippa Brice “EU legal amendments threaten genomic medicine and research” (23 October 2013) 
<www.phgfoundation.org>. 
92 Weiermiller, above n 36, at 143–144. 
93 See Section 41BEA of the Therapeutic Goods Act 1989 in conjunction with the Therapeutic Goods 
(Excluded purposes) Specification 2010. 
94 Dee Magin, Ben Hudson and Les Toop “Direct-to-Consumer Genetic Testing: Letting the Genie out of 
the Bottle” (2012) 125 NZMJ 7. 
95 At 10. 
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1 Existing fragmentary coverage by consumer protection law and medical law 
General consumer protection laws apply to the advertising of DTC testing as well as to 
the quality of the test results to a certain degree. If companies offer the delivery of a 
genetic risk report for a certain disease without a valid link between disorder and gene 
mutation, they violate s11 and s13(b) of the Fair Trading Act 1986. According to those 
provisions companies must not engage in conduct that is likely to mislead consumers 
about the suitability for a purpose, or use any false or misleading representation about the 
quality of a service. Additionally s8 and s29 of the Consumer Guarantees Act 1993 
require companies to deliver goods and services that are fit for the particular purpose., 
Apart from obviously fraudulent offers, the question of whether a DTC genetic testing 
company has been misleading about the predictive value of its test is difficult to answer. 
The inherent scientific insecurity raises particular problems for any assessment. What 
quality must scientific evidence have? How many GWA studies are considered sufficient 
to speak of reliable predictive value?  The scientific insecurity also makes it difficult to 
assess when test results can be considered fit for the claimed purpose of risk-prediction. 
Similar problems of assessment apply to the possible misleading character of the utility of 
the test. Is it deceptive to claim the possibility “to take truly control of your health and 
long-term well-being”, when the advice that results from the test do not go beyond 
general tips for a healthy lifestyle?96  
 
A further problem is the monitoring and enforcement of any of the above-mentioned 
provisions in regard to DTC genetic testing. In case of the Fair Trading Act 1986, the 
Commerce Commission, as the responsible agency for monitoring, will most likely lack 
the knowledge to validate the association of a SNP with a disease. Furthermore EasyDNA 
does not even disclose the relevant data on its website, but only after the purchase of the 
test in its report. Even if consumers are guaranteed that the testing service is fit for 
purpose, they are unlikely to have the necessary knowledge to understand that the test 
results are of little or no reliability. 
 
In comparison to absolute negative boundaries for advertising and trade conduct, positive 
regulation that requires the disclosure of certain information could be more useful to 
prevent any deceptive character.  In regard to advertisements the Therapeutic Products 
and Therapeutic Services Advertising Codes establish some standards.97 Because of their 
health-related purpose DTC genetic tests are subject to the industry-self regulating Codes 
of Practice. A mandatory pre-vetting process for any publication of advertisements in the 
  
96 Statement used by EasyDNA as advertising for their DNA Health Test <www.easydna.co.nz>. 
97 Both codes are available at <www.asa.co.nz>. 
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New Zealand media promotes a high standard of compliance with the Codes.98 
Irrespective of the question whether the standards in the mentioned Code of Practice are 
sufficiently specific for DTC genetic testing, the main deficiency is that companies 
advertise entirely through their websites. Whereas print advertising would be refused 
without evidence of pre-vetting, information on company owned websites cannot be 
controlled. The responsible agency Association of New Zealand Advertisers (ANZA) 
acknowledges this problem and encourages providers to get the agency´s approval before 
websites are launched in New Zealand.99 Yet, the incentive to get prior approval is 
limited.  
 
In regard to the information presented in the risk report, one may rightly ask whether 
New Zealand law does not require a certain degree of quality in specific legislation. 
Because genetic testing is traditionally viewed from a medical setting, one would expect 
to find provisions in the Medicines Act 1981 and the Medicines Regulations 1984. 
However, in regard to DTC genetic testing there are two problems. One is a question of 
scope of application, second is the absence of any kind of pre-approval process. 
 
The Medicines Act 1981 applies to medical devices which are defined as “any device, 
instrument or other article that is intended to be used in, on, or for human beings for a 
therapeutic purpose”.100 Therapeutic purpose includes “testing the susceptibility of 
persons to a disease or ailment”.101 The problem with DTC genetic testing is that the 
testing kit is certainly covered by the definition of medical device; however, the cotton 
swab itself is not the area of concern. Rather it is the service of providing a risk analysis 
report. In regard to health related DTC-products such a distinction between device and 
service is new. Taking the example of a pregnancy test, the result is shown on a display, 
so that any regulation for the device would incorporate the clinical validity of the test 
results. This is appropriate, because information is the main purpose of the test. With 
genetic testing, the test results are closely related to the device, however, test results are 
not part of the device, but are provided by an additional service. Similar loopholes have 
  
98 The responsible agency is the Association of New Zealand Advertisers (ANZA). See for more 
information on the pre-vetting process: Association of New Zealand Advertisers “TAPS Pre-vetting 
system” <www.anza.co.nz>. 
99 Association of New Zealand Advertisers “Guideline No. 14 - Advertising Therapeutic Products on 
Websites originating in New Zealand” <www.anza.co.nz>. 
100 Section 3A(a) of the Medicines Act 1981. 
101 Section 4(c) of the Medicines Act 1981. 
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been detected in European legislation and there are plans to incorporate health-related 
informational services.102 
Furthermore, even if related services to medical devices formed part of the scope of 
application of the Medicines Act 1981, the current regulatory system in New Zealand for 
medical devices relies almost completely on the industry’s voluntary compliance with 
international standards.103 Those standards are commonly known as ISO standards and do 
not yet cover genetic testing services.104 It is the manufacturers’ responsibility to assess 
the conformity and there is no pre-market approval for any sort of medical device.  
 
In this regard, DTC genetic tests fall through the current regulatory net. A quality 
assurance for a valid association between a gene mutation and an increased risk for the 
development of a disease is not yet established. Therefore, consumers find themselves 
entirely on their own in assessing the quality of the service offered. A task that is 
impossible without expert knowledge in the field of genetics.  
 
This finding is not surprising. In fact, the Ministry of Health concluded in its set of 
recently published cabinet papers, containing key elements for a new therapeutic products 
legislative regime, that current legislation has “significant gaps in coverage”, is “dated 
and inflexible” and gene technology is one example of “rapid development of new 
products that “are challenging the capacity and currency of regulatory systems 
globally”.105  
  
102 The current revision of the relevant Directive 98/79/EC would expand regulatory oversight on clinical 
validity und utility of the service undertaken by genetic testing companies. European requirements would 
apply irrespective of the physical basis of the laboratory or company whenever the service is offered to 
European costumers. 
103 The Medicines Act 1981 contains provisions regarding the quality and standard of medical devices in its 
s 35–s 42. Section 40 requires the compliance with prescribed standards for medicines and medical devices. 
Section 37 empower the Director General to prohibit the import of medical devices for a limited period of 
one year, whereas s 38 concerns the power to require evidence of the safety of a medical device and 
constitutes further sales before supplying the required evidence as a offense. Section 4 of the Medicines 
Regulations 1984 contains an equally broad “a medical device that is described as conforming to a 
particular description should conform to that description”. Section 62 of the Medicines Act 1981 prohibits 
the sale of medical devices that claim to operate with any form of radiation. 
104 The International Organization for Standardization (ISO) is an international, independent, non-
governmental organization consisting of 164 member countries, which has set over 21,000 standards in a 
wide range of industry fields, including health care. 
105 See Minister of Health Therapeutic Products Regulation Paper 1: Context and Overview (Ministry of 
Health, 28 April 2016) at [11]–[12]. 
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2 Recommendations  
This paper recommends that DTC genetic testing be on the schedule of both, industry 
regulators as well as government agencies.  
 
(a) Industry self-regulation as interim solution  
Regarding existing industry self-regulation for advertisement of therapeutic products and 
services, industry self-regulatory bodies as ANZA should take a more active role. ANZA 
should contact companies that are operating ‘co.nz’ websites and advise them that they 
have to comply with the existing Code of Practice. Such procedure should be feasible 
considering that the quantity of co.nz operating websites is relatively small. ANZA 
should complain about any lack of available evidence for clinical validity of the offered 
tests, as well as about the unbalanced information disclosure concerning benefits and 
limits of the test. At least, the approach would send a clear message that regulators expect 
companies advertising to New Zealand consumers to comply with the already existing 
industry codes. 
 
Furthermore, while developing a possible incorporation of DTC genetic testing in the 
new therapeutic products legislation (see below b)), it seems prudent to enter into a 
dialogue with DTC genetic testing companies with the aim of creating an industry code 
of conduct. There are several proposals from organisations and bodies of different 
countries.106 However, the industry itself is often not part of the negotiations. 
Interestingly, 23andMe, a large US based company has recently issued self-established 
guidelines about criteria for the inclusion of SNPs in their test and appropriate forms of 
result communication.107 An active approach towards collaboration could therefore be 
successful. 
 
(b) Incorporation of DTC genetic testing into a new statute for therapeutic 
products 
Although the development of an industry Code of Conduct and an active engagement of 
self-regulatory bodies as ANZA is a feasible short-term goal, a legislative regulation is 
considered the preferable option in order to give the industry a compulsory legal 
  
106 See for Australia: National Pathology Accreditation Advisory Council The Provision of Direct to 
Consumer Genetic Tests: Guiding Principles for Providers (May 2014); for the United Kingdom: UK 
Human Genetics Commission A Common Framework of Principles for direct-to-consumer genetic testing 
services (September 2009). 
107 Sheel Dandekar and others “White Paper 23-07: Guidelines on Vetting and Reporting Variants with 
Strong Effects on Health” (19 September 2014) 23andMe <eu.customercare.23andme.com>.  
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framework. The current review of the Medicines Act 1981 and the Medicines Regulations 
1984 provides an excellent opportunity to give particular attention to the issue of genetic 
testing services. 
 
The incorporation of genetic tests into a comprehensive regulatory regime for therapeutic 
products is preferable to a separate statute for genetic testing services. Medicines, 
traditional medical devices and new hybrid products as genetic tests that are combined by 
a product and a related service share all one feature: a therapeutic purpose. Whether the 
device itself achieves this therapeutic purpose or a related service is not decisive. What is 
important is the safety and quality of the product or related service. 
 
Therefore, as a first step, any definition of therapeutic products should explicitly include 
DTC genetic tests. Additionally, it should be clarified that genetic tests include the related 
service of delivering health-related information. The issue of clinical validity of test 
results would become part of the scope of application. A broader scope of application for 
a new therapeutic products legislation is also the preferred policy option in the 
Regulatory Impact Statement, which states that “all products and activities having a 
therapeutic purpose are subject to regulation”.108  
 
Secondly, it is crucial to establish requirements for a certain level of clinical validity of 
the test before it is placed on the market. Exact boundaries as to how many clinical 
studies must be done and the level of quality required to claim clinical validity of a 
genetic test is a difficult task. However, it is important to define exact criteria in order to 
perform a balancing act between the inherent scientific insecurities and the lack of 
specific knowledge of consumers. MedSafe should take advantage of the opportunity to 
promote international cooperation and coordination, encouraging foreign regulators such 
as the FDA and the European Medicines Agency to enter in dialogue regarding a 
potential set of minimum requirements. Already existing tools can serve as guidelines to 
determine a threshold for the validity of a gene-disease association, such as the Venice 
criteria.109 A desirable long-term objective is the creation of an ISO standard that 
considers the service of DTC genetic testing companies and possibly contains standards 
for the presentation of the results and a uniform calculation tool for personal risk 
  
108 Minister of Health Therapeutic Products Regulation Paper 2: Proposals for a Therapeutic Products Bill 
(Ministry of Health, 28 April 2016) at [19] and Ministry of Health Regulatory Impact Statement: 
Therapeutic Products Regulation (28 April 2016) at [90] and [93], (emphasis by author). 
109 Carolin F Wright, Allison Hall and Ron L Zimmern “Regulating direct-to-consumer genetic tests: What 
is all the fuss about?” (2011) 13 Genet Med 295 at 299, n 42. 
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assessment.110 Detailed requirements should be incorporated in subordinate law in 
regulations or regulator-made instruments in order to be flexible enough to cope with 
further developments in technology.111  
 
In regard to the pre-market approval the policy proposal for a new therapeutic product 
regulatory scheme follows the internationally recognised risk based classification of 
therapeutic products.112 This proposal is to be welcomed and would mean that different 
levels of pre-market control are put on all therapeutic products according to their risk 
classification.113 Depending on public budget and administrative costs, mandatory pre-
market approval by the responsible regulator could be limited to mid to high-risk 
products whereas low-risk products could be self-certified. Future international 
cooperation would also offer the possibility to accept foreign countries’ approval for the 
New Zealand market. In this way, public money is saved and the administrative burden 
for companies is reduced.  
 
There are two possibilities for how genetic tests should be assigned to risk groups. One is 
to make an assessment according to the severity of the condition that the test is associated 
with. The other possibility is to focus on the material that is analysed and therefore to 
group all genetic tests into one group. The latter approach is favoured in the current 
proposal of the European Parliament.114 This approach can be explained by the 
exceptional character of DNA, as explained in the first part of this paper. There are good 
reasons to treat genetic tests carefully because of the information tested, however, this 
paper supports the first option as a more proportionate and feasible solution. From a 
medical perspective, potential harm for consumers is influenced by the condition tested 
for. Whereas cancer and Alzheimer´s are severe conditions and no intervention is 
possible for the latter, results concerning obesity, migraine or diabetes present less 
  
110 Christine Hauskeller “Direct to Consumer Genetic Testing” (2011) BMJ 342 at 342. 
111 This flexible approach is in line with the current proposal of the Ministry of Health regarding possible 
classification of therapeutic products; see Minister of Health, Therapeutic Products Regulation Paper 2, 
above n 108, at [27]. 
112 In the US and Europe the market approval for genetic tests is classified according to their risk class: see 
for the US: Federal Food Drug and Cosmetic Act 21 USC § 360c and for Europe: European Commission 
Proposal for a Regulation of the European Parliament and of the Council on in vitro diagnostic medical 
devices COM(2012) 541 final (26 September 2012) Chapter VI art 39–46.  
113 Regulatory Impact Statement: Therapeutic Products Regulation (28 April 2016) at [124]. 
114 European Parliament Legislative resolution of 2 April 2014 on the proposal for a regulation of the 
European Parliament and of the Council on in vitro diagnostic medical devices P7_TA(2014)0267 (2 April 
2014) Chapter 1 Art 1 Number 6b(a). 
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psychological risks. Certainly, the boundaries are often blurred and what is considered as 
a severe condition may also be influenced by personal experiences. However, in this way 
tests for the most harmful conditions could be effectively monitored. Similar to quality 
requirements, details of classification (which disease is considered as severe etc.) should 
be made in regulations.  
 
Importantly, enforcement will remain the main problem of DTC genetic testing due to a 
global market without any restriction of access, as acknowledged in the current European 
debate.115 However, international collaboration is a first step in the right direction and 
industry will be prompted to notice that it will not be permitted to ‘slip through the net. 
Furthermore, there should be enhanced public education to make consumers aware of the 
risks of ordering DTC genetic testing services online, especially from websites outside 
New Zealand.  
B Improving the Informed Consent Process  
1 Status quo 
The second issue that was identified was the assurance of valid informed consent for 
DTC genetic testing. At first glance, New Zealand seems well prepared with a wide 
ranging Code of Health and Disability Services Consumers’ Rights (Code of Rights) as 
part of the Regulations under the Health and Disability Commissioner Act 1994 (HDC 
Act), and specific provisions in the Human Tissue Act 2008.  
 
(a) General provisions 
The Code of Rights uses the terms ‘consumer’ and ‘provider’ and provides for certain 
rights of the consumer and corresponding duties of the provider. Provider is defined as 
health care provider and is according to the relevant definition in the HDC Act 1994 
every person who provides health services to the public.116 The frequently heard 
argument of DTC genetic testing companies, that they do not provide any health care, is 
likely to be dismissed because s 2(1) of the Act defines the term health treatment (as a 
  
115 Louiza Kalokairinou, Heidi C Howard and Pascal Borry “Current developments in the regulation of 
direct-to-consumer genetic testing in Europe” (2015) 15 Medical Law International 97 at 105. 
116 The definitions for terms used but not explicitly defined in the Code of Rights itself, must be read in 
light of the related statute law, the HDC Act 1994. This is by virtue of s 34 of the Interpretation Act 1999, 
which provides: 
“A word or expression used in a regulation, Order in Council, Proclamation, notice, rule, bylaw, 
Warrant, or other instrument made under an enactment has the same meaning as it has in the enactment 
under which it is made.” 
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subcategory of health service) to include taking of human tissue for educational purposes. 
Even if the intention of legislator was probably the collection of tissue for anatomy 
courses etc., it can be argued that DTC genetic companies provide at least an educational 
service to their costumers when they provide the genetic profile information. In regard to 
informed consent, the Code provides in Right 6 for an extensive right to be fully 
informed about the service and in Right 7(1) for mandatory informed consent prior to any 
service. Furthermore para 6 requires written consent for any participation in research and 
para 10 refers explicitly to the use of body material. Furthermore s 19(1)(b) and (c) of the 
Human Tissue Act 2008 require informed consent for the collection, as well as for the 
analysis of non-health care tissue. DTC Genetic Testing Services fall within that 
denomination.117  
 
Irrespective of the wide application of the mentioned statutes, it is still questionable 
whether overseas-based companies will comply with the provisions. Companies can 
argue that they use choice of law clauses in their TAC (consumers often agree to US 
American law to govern their contract) and are therefore not subject to specific legislation 
in New Zealand. In regard to the TAC of EasyDNA, the provision about deemed consent 
for participation in research (see above III B 2(b)) seems particularly questionable. It is 
certainly not the intention of the Code of Rights that companies can privately contract out 
of the provisions of the Code. In fact, to include such substantive information in the mass 
of TAC contradicts the duty of the provider to disclose information in a comprehensive 
way. Furthermore, it is important to consider whether more positive regulation is needed 
to give guidance as to what is expected from commercial companies in order to comply 
with their duties under the Code of Rights.  
 
(b) Provisions applying to testing of minors and involuntary testing 
In regard to DTC genetic testing of minors and involuntary testing, s 33 (2) of the Human 
Tissue Act 2008 always requires the informed consent of the person tested, therefore 
prohibits any consent on behalf of minors. Furthermore s 23 declares any collection or 
use of human tissue without the required informed an offence with a possible conviction 
to imprisonment for 1 year or a fine not exceeding $50,000 NZD. 
 
  
117 Section 6 defines non-health-care tissue as human tissue that is collected from a human body but outside 
of a health care procedure and donor analysis according to s 6 includes analysis with the purpose to provide 
information (also genetic information) about an actual or potential condition or trait of the individual. 
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2 Recommendations  
(a) Mandatory pre-test counselling 
The question as to how far intervention should go to achieve a safer informed consent 
process is a delicate one.   
One solution could be more balanced and understandable information by positive 
regulation for mandatory information to be provided on websites. Indeed, the policy 
should not create an information overload, as this would not serve the purpose of 
consumer´s understanding of the information. However, mandatory disclosure could 
ensure that companies do not hide negative information in disclaimers in their TAC. 
Some authors consider a system of mandatory information disclosure as sufficient and 
proportional regulation of DTC genetic testing.118  
 
However, this paper argues for a stricter approach than only positive informational 
obligations. There should be the safeguard of a human interaction to ensure informed 
consent. Despite the obvious enforcement problem, this paper argues at least for a 
mandatory pre-test counselling.119 In comparison to the European proposal, this 
recommendation does not require a medical prescription but a consultation meeting. 
Additionally, despite the mandatory pre-counselling, the disclosure of the results would 
still be available without the involvement of a physician. However, it would be desirable 
that some form of deliberate consumer action (extra click) is needed before test results for 
severe conditions (e.g. Alzheimer´s disease and all forms of cancer) are displayed. 
Voluntary post-counselling would give consumers the benefit of privacy whereas pre-
counselling could provide an incentive to discuss results in a follow-up session with the 
health care professional.  
 
Such a regulatory approach certainly intervenes to a larger extent with the business of 
DTC companies and channels the access to DTC genetic testing for consumers. However, 
this paper argues that it is negligent to wait for the evidence of harm where risks are not 
only to individuals themselves but also society as a whole. Waiting for evidence would 
mean acceptance of the occurrence of damage. A careful and proactive approach seems 
preferable. 
  
118 See for example proposals in Bunnik, Cecile and Schwermer, above n 62, at 349 who propose a 
combined tiered-layered-staged model of informed consent applicable to online offers; See also Nuffield 
Council on Bioethics, above n 52, at 158, who argues that further evidence of actual harm is needed for 
stricter state regulation and propose a combination of an Industry Code of Practice, strict regulatory 
oversight of advertising claims and public education. 
119 See with the same approach in the US: Piehl, above n 23, at 92. 
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Mandatory pre-counselling offers a chance to minimise the issues in relation to informed 
consent. Doctors as a human intermediary and a neutral information source could assure 
that risks and benefits are understood. With a conformation number or similar evidence, 
consumers could then purchase the test. Especially when consumers make their purchase 
decision out of curiosity, written information may be overlooked. The benefits of a 
human interaction in comparison to self-study of written information are persuasive. A 
medical professional could give tailored advice and information according to the 
consumer’s motive for testing. Hence, a woman who considers testing for BRCA 
mutation could get more detailed information about the current stage of scientific 
evidence, which can clear any misunderstanding about the test’s significance.  
 
It has to be clear that a mandatory pre-counselling service would not mean a complete 
shift of responsibility from the commercial companies to doctors; rather companies 
would remain responsible for sufficient and balanced information, however, the doctor 
would be a further safeguard ensuring consumers understand the information and 
misinterpretations are detected before the purchase. A benefit of such partial involvement 
of medical professionals in the DTC genetic testing service is therefore an increased 
incentive for companies to refrain from using exaggerated advertising on their websites 
and to obtain available quality seals in the future. To avoid any conflict of interest, pre-
counselling must not be provided by company-employed doctors but rather by a list of 
independent medical professional available on the website.  
 
Undoubtedly there are challenges with the proposed pre-counselling. One is a practical 
question of financing. It does not seem fair that public funds are used for the benefit of 
private companies. Companies should be obligated to pay a user fee for every consumer 
into a public fund. A further problem is a potential evasive attitude of medical 
professional who are forced into a ‘marriage’ with the genetic testing industry. 
Considering that most tests do not show clinical utility, some argue that mandatory 
medical advice is useless.120 However, it is already a reality that genetic testing has an 
influence on traditional medical health care. With further development and growing 
demand, doctors will be more often confronted with commercial offers. The already 
proposed establishment of certain quality criteria for clinical validity and pre-market 
approval is also beneficial for effective consultation.  
 
  
120 Wright, Hall and Zimmern, above n 109, at 299. 
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The mandatory pre-counselling should be incorporated in the current review of the 
Medicines Act. The cabinet papers already propose to introduce a system similar to the 
current classification of medicine (prescription only, pharmacy-only, general sale) 
applicable to all therapeutic products. E.g. the term ‘prescription’ is defined more broadly 
as ‘available on the authority of a health practitioner’.121 In this section the legislation 
could refer specifically to genetic testing services and introduce a counselling 
requirement. 
 
(b) Prescription requirement for testing of minors and additional ban of 
advertisement  
In line with the existing provisions, DTC genetic testing of minors should only be 
available with a medical prescription. In contrast to adult testing, a clear medical benefit 
for the minor should be the result of any test. This restriction is necessary to ensure the 
minor’s right not to know and to avoid any negative impact on a child’s personality and 
development. Additionally advertising for genetic testing of minors should be banned 
completely.  
 
Furthermore consumers should be warned in an explicit manner during ordering process 
that any sending of samples without the required consent of the source is an offence and 
can be prosecuted. Admittedly, such warning statements cannot provide absolute 
certainty and in particular, the protection of minors may be an argument to justify a 
prescription requirement for all genetic tests, especially considering the fast development 
of the genetic science.  
C Reducing the Risk of Psychological Harm and Fulfilling Responsibilities to Society 
Finally, the combination of the policy recommendations in the last two sections can, to a 
certain extent, reduce the risk of psychological harm. Pre-counselling can prevent 
unnecessary concerns due to misunderstanding of the test results’ significance. 
Additionally, quality requirements for genetic tests help to make the market more 
transparent for consumers. With the channeling of consumers through a human 
intermediary government can also meet its responsibility towards current and future 
society, because policy makers are able to better monitor the long-term development of 
the industry and its impact on society. 
 
  
121 Minister of Health Therapeutic Products Regulation Paper 2, above n 108, at [32]. 
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V Conclusion 
This paper has made recommendations on how to achieve adequate consumer protection 
without compromising potential benefits of the new DTC genetic testing industry. The 
proposals include a broader scope of application for the new therapeutic products 
legislation, a partial involvement of a health care professional as well as legislative 
requirements for pre-market approval and quality criteria that ensure a certain level of 
clinical validity despite the inherent scientific insecurities. However, it is acknowledged 
that this framework may need further economic analysis and is to some extent also 
influenced by value judgments, such as the requirement to protect sensitive genetic 
information and a responsibility towards future generations and society.  
 
The current revision of New Zealand’s therapeutic products regimen provides an 
excellent opportunity to engage in a political dialogue and to set the right course in a new 
regulatory framework. Furthermore, against the backdrop of an online market place, 
consumers would greatly benefit from international co-ordination and cooperation. With 
a holistic approach, New Zealand can set the standards to be best prepared both for 
today´s and for future developments in the genetic testing industry. 
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